Borregaard (BRG) Pre-close call summary
Event summary combining transcript, slides, and related documents.
Pre-close call summary
19 Mar, 2026Executive summary
Sales volumes for BioSolutions expected at 340,000 tonnes for 2026, with growth in agriculture; Q1 volume in line with prior year at 80,000 tonnes.
BioMaterials sales forecast at 155,000-160,000 tonnes in 2026, up from 146,000 tonnes in 2025; specialized grades to see slight growth.
Fine Chemicals sales prices for bioethanol expected to remain stable; intermediates volume to increase.
Trading performance and revenue trends
BioSolutions growth driven by agriculture, but construction and oilfield chemicals markets remain weak.
BioMaterials average sales price expected to decline 3%-4% in H1 2026 due to product/customer mix and selective price adjustments.
Additional 4,000-5,000 tonnes to be sold in 2026 due to prior production disruption.
Profitability and margins
EBITDA for BioSolutions in 2025 not much stronger than 2024 due to increased costs, especially at U.S. plants and above-inflation cost rises.
Wood costs expected to be 15% lower in H1 2026 versus H1 2025, partially offsetting higher energy costs.
Latest events from Borregaard
- Record EBITDA, strong cash flow, higher dividend, and start-up impairments define the period.BRG
Q4 20254 Feb 2026 - BioSolutions strength offset weaker BioMaterials; outlook cautious amid rising costs.BRG
Q2 20243 Feb 2026 - Specialization, innovation, and sustainability drive robust growth and disciplined investment.BRG
CMD 202420 Jan 2026 - Q3 revenue and EBITDA rose on volume growth and expansion, but cost and market risks remain.BRG
Q3 202417 Jan 2026 - Strong growth, sustainability, and expansion drive value in advanced biorefinery markets.BRG
SEB Nordic Seminar presentation16 Jan 2026 - Record EBITDA and higher dividend driven by BioSolutions, with strong outlook for 2025.BRG
Q4 20249 Jan 2026 - 2025 outlook: stable volumes, higher biomaterials prices, lower bioethanol prices, and cost risks.BRG
Pre-Close Call26 Dec 2025 - Q4 guidance remains steady, with strong margins and lower costs offset by ongoing legal and market risks.BRG
Pre-Close Call18 Dec 2025 - Record BioSolutions results and improved margins drove EBITDA to NOK 511 million.BRG
Q1 202529 Nov 2025